ClinicalTrials.gg
Not yet recruitingNCT06397274Updated May 2, 2024

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

A Phase 2 interventional study of Stemchymal and Placebo in Spinocerebellar Ataxias, sponsored by Steminent US, Inc.. Not yet recruiting. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Steminent US, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

02

Conditions studied

  • Spinocerebellar Ataxias
03

In context

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

This study's planned enrollment of 20 is below the median of 29 across 61 interventional studies indexed under Spinocerebellar Ataxias.

Browse Spinocerebellar Ataxias studies →

Lead sponsor

This is the only study on the registry with Steminent US, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are with genotypically confirmed SCA3.
  2. Subjects' SARA scores are in the range of 5 to15.
  3. Subjects are between 20 and 70 years of age.
  4. Subjects who have signed .
  5. Female subjects of who are capable of conception must be (one year or greater without menses), surgically incapable of childbearing, or practicing effective methods of .
  6. Male subjects must be practicing a medically accepted form of contraception during the study period. Abstinence is an acceptable method of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have been enrolled in any kind of cell therapy within six months prior to screening visit (Visit 1).
  2. Female subjects who have a positive pregnancy test result.
  3. Subjects who have had severe vital organ diseases, including but not limited to cardiac (e.g., heart failure), liver (e.g., acute hepatic failure or chronic liver cirrhosis), lung (e.g., respiratory failure) and renal (e.g., hemodialysis or peritoneal dialysis) diseases, within six months prior to screening visit (Visit 1).
  4. Subjects with immunological disorders (e.g., systemic lupus erythematosus), within six months prior to screening visit (Visit 1).
  5. Subjects with other neurological disorders (e.g., Alzheimer's disease), within six months prior to screening visit (Visit 1).
  6. Subjects who had received chemotherapy/radiotherapy within five years prior to screening visit (Visit 1).
  7. Subjects with any history of malignant tumors.
  8. Subjects with dementia or other psychiatric illnesses, including but not limited to disabling depression, bipolar disorder, schizophrenia.
  9. Subjects with a Beck Depression Inventory Second Edition (BDI-II) score of over 20 points.
  10. Subjects not suitable for this clinical trial according to investigator's judgment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Stemchymal®

    Biological: Stemchymal

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalStemchymal

    Patients will receive Stemchymal® through intravenous infusion

  • BiologicalPlacebo

    Patients will receive Placebo through intravenous infusion

06

What researchers measure

Primary outcomes

  1. Change of Scale for the Assessment and Rating of Ataxia (SARA) scores from baseline (week 0) at 6 months (week 24).

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jun 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartEst.
Jun 1, 2025
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06397274
Lead sponsor
Steminent US, Inc.
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Jun 1, 2025 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
May 2, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion